Endocannabinoids and the haematological system

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 671-675

  Randall, M D ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

2 arachidonoyl glycerol; Anandamide; Cannabinoids; Endocannabinoids; Endothelium; Fatty acid amide hydrolase; Haematopoesis; Platelets; Thrombosis

Indexed keywords

ENDOCANNABINOID;

ATHEROSCLEROSIS; BLOOD CELL; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; ENDOTHELIUM; HEMATOLOGY; HEMATOPOIESIS; HUMAN; HYPOTENSION; INFLAMMATION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN TRANSPORT; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOGENICITY;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; ENDOCANNABINOIDS; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; HEMATOPOIESIS; HUMANS; MODELS, BIOLOGICAL; PLATELET ACTIVATION;

EID: 35648930987     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707420     Document Type: Review

References (35)

1. Akerman S, Kaube H, Goadsby PJ (2004). Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 142: 1354-1360.
2. Aronow WS, Cassidy J (1974). Effects of marijuana and placebo-marijuana smoking on angina pectoris. New Engl J Med 291: 65-67.
3. Berdyshev EV, Schimd PC, Krebsbach RJ, Schmid HHO (2001). Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J 15: 2171-2178.
4. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.
5. Bojesen IN, Hansen HS (2005). Membrane transport of anandamide through resealed human red cell membranes. J Lipid Res 46: 1652-1659.
6. Braud S, Bon C, Touqui L, Mounier C (2000). Activation of rabbit platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett 471: 12-16.
7. Croxford JL, Yamamura T (2005). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmun 166: 3-18.
8. Cupini LM, Bari M, Battista N, Argiro G, Finazzi-Argo A, Calabresi P et al. (2005). Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 26: 277-281.
9. Deusch E, Kress HG, Kfraft B, Kozek-Langenecker SA (2004). The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 99: 1127-1130.
10. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA et al. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglyerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267.
11. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB (1998). Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54: 180-188.
12. 3H]anandamide by rabbit platelets. Lack of transporter? Eur J Biochem 270: 3498-3506.
13. Gauthier KM, Baewar DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS et al. (2005). Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol 288: H1344-H1351.
14. Ho W-SV, Randall MD (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150: 641-651.
15. Jorda MA, Rayman N, Tas M, Verbakel SE, Battista N, Van Lom K et al. (2004). The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either produces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104: 526-534.
16. Jorda MA, Verbakel SE, Valk PJM, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agro A et al. (2002). Haematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99: 2786-2793.
17. Maccarrone M, Bari M, Battista N, Finazzi-Argo A (2002). Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 100: 4040-4048.
18. Maccarrone M, Bari M, Del Principe D, Finazzi-Agro A (2003). Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 89: 340-347.
19. Maccarrone M, Bari M, Menichelli A, Del Principe D, Finazzi-Agro A (1999). Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 447: 7-282.
20. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A (2001a). Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 268: 819-825.
21. Maccarrone M, De Petrocellis L, Bari M, Fezza F, Salvati S, Di Marzo V et al. (2001b). Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 393: 321-328.
22. Malorni W, Bari M, Straface E, Battista N, Matarresse P, Finazzi-Argo A et al. (2004). Morphological evidence that 2-arachidonoylglycerol is a true agonist of human platelets. Thromb Haemost 92: 1159-1161.
23. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M (1998). Carbachol, an acetylcholine receptor agonist, enhances production in the rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 362: R1-R3.
24. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. Circulation 103: 2805-2809.
25. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
26. Randall MD, Kendall DA, O'Sullivan SE (2004). The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26.
27. Rodondi N, Pletcher MJ, Liu K, Hulley SB, Sidney S (2006). Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). Am J Cardiol 98: 478-484.
28. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low doses of oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786.
29. Valk P, Verbakel S, Vankan Y, Hol S, Mancham S, Ploemacher R et al. (1997). Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for haematopoietic cells. Blood 90: 1448-1457.
30. Varga K, Wagner JA, Bridgen DT, Kunos G (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044.
31. Vogeser M, Hauer D, Azad SC, Huber E, Storr M, Schelling G (2006). The release of anandamide from blood cells. Clin Chem Lab Med 44: 488-491.
32. Volfe Z, Dvilansky A, Nathan I (1985). Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res 5: 243-246.
33. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518-521.
34. Walter L, Stella N (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785.
35. Zolese G, Bacchetti T, Ambrosini A, Wozniak M, Bertoli E, Ferrett G (2005). Increased plasma concentrations of palmitoylethanolamide, endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: an in vitro study. Atherosclerosis 182: 47-55.